Oral GLP-1s Won’t Win on Convenience – They’ll Win on CMC
GLP-1 peptides validated the science. CMC will validate the small molecule modality for GLP-1 efficacy, scalability, and access.
False
Advertisement
Related Content
Drug Delivery
Cell & Gene
Industry News
Prula-cel Shows Early Promise in Lupus
October 8, 2026
2 min read
Adicet Bio reports 12-month remission and renal response data for its allogeneic gamma delta CAR T therapy
Small Molecules
Small Molecules
Formulation
The Confidentiality Barrier to AI-Enabled Drug Development
July 27, 2026
3 min read
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
Small Molecules
Small Molecules
Business & Trends
Why Drug Development Still Lacks Integration
July 21, 2026
4 min read
John McDermott reflects on why early drug development remains fragmented – and how integrated approaches may shorten timelines
Cell & Gene
Drug Delivery
Development & Clinical
In Vivo CAR T: A New Route to Treating Autoimmune Disease
July 13, 2026
6 min read
How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments